On May 29, 2025, Roivant Sciences reported its financial results for the fourth quarter and fiscal year ended March 31, 2025. As of March 31, 2025, the company held approximately $4.9 billion in cash, cash equivalents, restricted cash, and marketable securities. This substantial liquidity position supports ongoing pipeline development and strategic initiatives.
For the fourth quarter, research and development (R&D) expenses increased by $37.7 million to $145.2 million compared to $107.6 million in the prior year's quarter, driven by increased program-specific costs for the anti-FcRn franchise and mosliciguat. General and administrative (G&A) expenses rose by $39.0 million to $147.1 million, primarily due to higher share-based compensation. The loss from continuing operations, net of tax, was $252.4 million for the quarter, compared to $95.0 million in the prior year.
For the full fiscal year 2025, R&D expenses increased by $110.5 million to $550.4 million, and G&A expenses increased by $175.3 million to $591.4 million. The company reported a loss from continuing operations, net of tax, of $729.8 million for the fiscal year, compared to income of approximately $4.5 billion in fiscal year 2024, which included the Telavant gain. Roivant also completed the repurchase of 128,631,786 shares for $1,294.85 million under its share buyback program announced on April 2, 2024, with 27,126,867 shares repurchased for $292.06 million between January 1 and March 31, 2025.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.